Cargando…

An Open-label, Multicenter Study to Assess the Efficacy and Safety of a Novel Probiotic Blend in Patients With Functional Gastrointestinal Symptoms

GOAL: A novel 5-strain (Bl-04, Bi-07, HN019, NCFM, and Lpc-37) probiotic blend was developed and its safety and efficacy were evaluated in patients with functional gastrointestinal (GI) symptoms. BACKGROUND: These strains administered together have not previously been investigated. STUDY: Patients a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Lucinda A., Cash, Brooks D., Moftah, Karim, Franklin, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Alimentary Tract: Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989638/ https://www.ncbi.nlm.nih.gov/pubmed/34028393 http://dx.doi.org/10.1097/MCG.0000000000001567

Ejemplares similares

Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases
por: Zhang, Hu, et al.
Publicado: (2020)

Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study
por: Ianiro, Gianluca, et al.
Publicado: (2020)

Selective expansion of intraepithelial lymphocytes expressing the HLA-E–specific natural killer receptor CD94 in celiac disease()()
por: Jabri*, ‡, §, Bana, et al.
Publicado: (2000)

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine
por: Siniscalchi, Monica, et al.
Publicado: (2020)

Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey
por: Marasco, Giovanni, et al.
Publicado: (2020)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
por: Bossa, Fabrizio, et al.
Publicado: (2021)

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
por: Maconi, Giovanni, et al.
Publicado: (2021)

Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area
por: Elli, Luca, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
por: Arrigo, Serena, et al.
Publicado: (2021)

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023)

The natural history of COVID-19 in vaccinated inflammatory bowel disease patients
por: Viazis, N., et al.
Publicado: (2023)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Multicenter prospective registration study of efficacy and safety of capsule endoscopy in Crohn’s disease in Japan (SPREAD-J study)
por: Sakurai, Toshiyuki, et al.
Publicado: (2023)

Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I
por: Nishida, Toshirou, et al.
Publicado: (2015)

Mucin Gene Deficiency in Mice Impairs Host Resistance to an Enteric Parasitic Infection
por: Hasnain, Sumaira Z., et al.
Publicado: (2010)

IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease
por: Tremelling, Mark, et al.
Publicado: (2007)

Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact With Hartnup Mutations
por: Camargo, Simone M.R., et al.
Publicado: (2009)

Multicenter prospective in vivo study of an endocytoscope system (ECS) for superficial esophageal cancer
por: Morita, Shuko, et al.
Publicado: (2021)

Potent inhibitory effect of alcoholic beverages upon gastrointestinal passage of food and gallbladder emptying
por: Kasicka-Jonderko, Anna, et al.
Publicado: (2013)

Composite detection rate as an upper gastrointestinal endoscopy quality measure correlating with detection of neoplasia
por: Romańczyk, Marcin, et al.
Publicado: (2021)

Mortality and cancer in eosinophilic gastrointestinal disorders distal to the esophagus: nationwide cohort study 1990–2017
por: Bledsoe, Adam C., et al.
Publicado: (2022)

Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)
por: Nakase, Hiroshi, et al.
Publicado: (2022)

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis
por: Kobayashi, Taku, et al.
Publicado: (2017)

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
por: Watanabe, Kenji, et al.
Publicado: (2019)

Intra‐gastrointestinal amyloid‐β1–42 oligomers perturb enteric function and induce Alzheimer's disease pathology
por: Sun, Yayi, et al.
Publicado: (2020)

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
por: Kakuta, Yoichi, et al.
Publicado: (2018)

Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation
por: Tanaka, Yukari, et al.
Publicado: (2022)

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis
por: Nagahara, Akihito, et al.
Publicado: (2013)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2011)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial
por: Nakajima, Atsushi, et al.
Publicado: (2017)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2012)

The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients
por: Jordi, Sebastian Bruno Ulrich, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
por: Schreiber, Stefan, et al.
Publicado: (2018)

Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials
por: Huang, Qiuyue, et al.
Publicado: (2021)

Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2017)

Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study
por: Kasugai, Kunio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1ena15jp59br32qfuag3cn6i72